By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TapImmune Inc. 

2815 Eastlake Avenue East
Suite 300
Seattle  Washington  98102  U.S.A.
Phone: 866-359-7541 Fax: n/a




Company News
TapImmune Inc. (TPIV) Announces $1,464,000 Million Registered Direct Offering 1/12/2015 9:27:40 AM
TapImmune Inc. (TPIV) Release: Positive Phase 1 Immune Responses In All Evaluable Ovarian And Breast Cancer Patients Advances Vaccine To Phase 2 Clinical Trials 1/12/2015 8:50:40 AM
Published Review and Analyst Report Boost TapImmune Inc. (TPIV) Shares 11/20/2014 2:37:19 PM
VGTI Florida To Collaborate With TapImmune Inc. (TPIV) To Advance Targeted Breast And Ovarian Cancer Vaccines Into Phase 2 Clinical Trials 11/19/2014 12:06:31 PM
TapImmune Inc. (TPIV) Announces Phase 2 Clinical Trials Collaboration With VGTI Florida To Advance Breast And Ovarian Cancer Vaccines 11/18/2014 10:26:08 AM
TapImmune Inc. (TPIV) Provides Update On Polystart™ Vaccine Platform Applicable To Cancer And Infectious Disease 10/22/2014 7:41:11 AM
TapImmune Inc. (TPIV) CEO Provides Update On Corporate Activity And Progression Of Clinical Programs 9/23/2014 10:48:54 AM
TapImmune Inc. (TPIV) Releases Positive Interim Data On Phase I Clinical Trial Of Folate Receptor Alpha Antigens In Ovarian And Breast Cancer 9/16/2014 8:55:22 AM
TapImmune Inc. (TPIV) Announces $2 Million Registered Direct Offering 8/11/2014 10:42:10 AM
TapImmune Inc. (TPIV)'s New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens 8/7/2014 11:08:05 AM